Acusensus heads into this earnings reaction with the stock at A$1.28 after a firm 30 day run, yet the headline numbers tell a more conflicted story. The company delivered record FY26 revenue of A$86.2m and adjusted earnings before interest, tax, depreciation and amortisation of A$8.5m, while still reporting a statutory loss driven by a one off A$16m litigation settlement. The market now has to decide whether today’s price reflects excitement about contracted FY27 growth or indicates too little concern about a business that is growing fast but still loss making.
Love the contracted growth story at Acusensus but concerned that it is still loss making? Check out the 10 resilient stocks with low risk scores for ideas that pair solid fundamentals with lower risk profiles.
FY 2026 Earnings Summary
- Revenue (FY 2026): A$87.2m vs. A$59.4m in FY 2025 (up about 47%)
- Net Loss (FY 2026, excluding extra items): A$24.3m loss vs. A$2.6m loss in FY 2025 (loss widened materially)
- Basic EPS (FY 2026): A$0.16 loss per share vs. A$0.02 loss per share in FY 2025 (loss per share increased sharply)
- Adjusted EBITDA (FY 2026): A$8.5m vs. A$5.7m in FY 2025 (up about 49%)
Prefer clean visuals instead of another dense wall of earnings tables and footnotes? See Acusensus’ full financial picture, including a clear view of its recent profitability track record, in the easy to read company report for Acusensus.
Acusensus Bull Case Hinges On Contracted Scale
Bulls argue Acusensus is shifting from one off project wins to a contracted, scalable platform. The FY26 result gives some support to that view. Group revenue reached A$86.2m with adjusted EBITDA of A$8.5m, and management now points to A$220m of remaining contracted work. For the current year, FY27 revenue guidance sits at A$100 to A$106m with about A$97m already under contract, which is a concrete milestone for the revenue visibility argument.
The thesis also leans heavily on international expansion and Forsite. International revenue of A$22.9m now makes up 27% of group revenue and moved to A$3m of adjusted EBITDA, which shows early operating traction outside Australia. Forsite is still small at about A$0.4m revenue, even with multi year customers, so the claim that subscription style income will reshape the mix remains more promise than delivered result.
Compare Acusensus’ contracted revenue pipeline and growing international contribution with how the street is framing the story at A$1.28 today, then see whether analyst targets echo the bullish case or point to more caution by checking the consensus price target analysis for Acusensus.Acusensus Bears Still Worried About Cash And Contract Quality
The cautious view on Acusensus says the growth story is masking fragile cash generation, lumpy hardware exposure and uncertain contract quality, especially offshore. This result does not fully ease those worries. Operating cash flow excluding the litigation settlement was A$3m, which is down from A$8.3m the prior year, even as adjusted EBITDA reached A$8.5m. That supports the concern that hardware heavy deployments still strain working capital and capex.
Bears also argue that international and U.S. investments may stay ahead of revenue. International moved into A$3m of adjusted EBITDA, yet management still expects the U.S. to weigh on group EBITDA in FY27. The backlog looks strong at A$220m with A$97m of FY27 revenue already contracted, but some U.S. programs are funded year by year. That validates the risk that apparent visibility can soften quickly if tenders or renewals slip.
After weaker cash conversion and year-by-year funded U.S. contracts, it is fair to ask whether these pressures hint at deeper structural issues. Review our independent risk analysis for Acusensus which shows 1 important warning signStay Ahead With Simply Wall St
If Acusensus’ contracted revenue pipeline and ongoing losses have your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how new contracts and cash flow trends affect the setup. Once you decide to take a position, keep your decisions focused with the Portfolio Command Center that highlights key events on your holdings and filters out background noise. For a longer term view, tap into collective insight through the Community and see how other investors are interpreting the same data. This can help you spot potential catalysts or emerging risks earlier and stay ahead of the broader market.
Seeking Alternatives Beyond Acusensus?
Fresh opportunities can move from quiet to crowded quickly. Some stocks are building momentum while they are still under the radar for now.
- Spot companies with strong balance sheets before the crowd rotates back to quality by reviewing the curated list of solid balance sheet and fundamentals stocks (20 results).
- Target potential payout workhorses that could support income portfolios with steady cash returns by scanning the hand picked 6 dividend fortresses.
- Catch early movers in sectors gaining quiet momentum by checking the carefully filtered 10 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com